A 26-week, prospective, open-label, uncontrolled, multicenter study to evaluate the effect of an escalating-dose regimen of trandolapril on change in blood pressure in treatment-naive and concurrently treated adult hypertensive subjects (TRAIL)

Tytus, Richard; Burgess, Ellen; Assouline, Linda; Vanjaka, Anita

doi:10.1016/j.clinthera.2007.02.016

Cited by 7 publications

(3 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Trandolapril has been approved by the US Food and Drug Administration in the US in 1996 and in Canada in 1997 for the treatment of patients with mild to moderate hypertension. Many controlled clinical trials have found that trandolapril, alone or in combination with other antihypertensive agents, produces clinically signifi cant blood pressure (BP) reductions and achieves target BP levels in patients with primary HTN (Mancia et al 1992;Guller et al 1993;Cesarone et al 1994;Omboni et al 1995;Guay 2003;Pepine et al 2003;Tytus et al 2007) TRAIL (The Canadian Study of Trandolapril on Blood Pressure in Hypertensive Patients) was a 26-week, prospective, open-label, multicenter study in Canadian primary care centers (Tytus et al 2007). Subjects with HTN stages I and II according to the 7-JNC (Chobanian et al 2003) who were treatment naive or whose disease was uncontrolled on current fi rst-line antihypertensive monotherapy, were treated with trandolapril alone or in addition to their current regimen.…”

Section: Patients With Hypertensionmentioning

confidence: 99%

Update on the use of Trandolapril in the management of cardiovascular disorders

Díaz

Ducharme²

2008

VHRM

View full text Add to dashboard Cite

Abstract:Trandolapril is a well known angiotensin converting enzyme (ACE) inhibitor with many cardiovascular (CV) indications. The objectives of this article are to review the pharmacokinetics and pharmacodynamics properties of trandolapril and to focus on its clinical relevance in cardiovascular medicine. Various populations have been studied in large clinical trials including patients with congestive heart failure (CHF) after an acute myocardial infarction (AMI), diabetics, patients with hypertension (HTN), stable coronary artery disease (CAD) and prevention of proteinuria. Long-term treatment with trandolapril in patients with reduced left ventricular function soon after AMI signifi cantly reduced the risk of overall mortality, mortality from CV causes, sudden death, and the development of severe CHF. Treatment with trandolapril after AMI complicated by left ventricular dysfunction appears to be of considerable importance in patients with diabetes mellitus by saving lives and substantially reducing the risk of progression to severe CHF as well. Moreover, trandolapril reduces progression to proteinuria in high-risk patients. Some of the advantages of trandolapril over other ACE inhibitors are the wide spectrum of patient populations studied, the well established dosage and its proven trough-to-peak effect ratios permitting a safe once-a-day administration.

show abstract

Section: Patients With Hypertensionmentioning

confidence: 99%

Update on the use of Trandolapril in the management of cardiovascular disorders

Díaz

Ducharme²

2008

VHRM

View full text Add to dashboard Cite

show abstract

“…In the Danish TRACE study (Trandolapril Cardiac Evaluation) in patients with left ventricular dysfunction soon after myocardial infarction, trandolapril markedly reduced the risk of overall mortality, mortality from cardiovascular causes, sudden death, and the development of severe heart failure [ 114 ]. A titration-based, escalating-dose regimen of trandolapril was suggested to be effective and well tolerated in the management of subjects who were antihypertensive treatment naive or whose disease was uncontrolled on a diuretic or calcium channel blocker [ 115 ]. The fi xed-dose combination of trandolapril and verapamil SR in patients with hypertension including those with type 2 diabetes mellitus was more effective than monotherapy [ 116 ].…”

Section: Trandolaprilmentioning

confidence: 99%

Drugs Targeting RAAS in the Treatment of Hypertension and Other Cardiovascular Diseases

Balakumar

Jagadeesh

2015

Pathophysiology and Pharmacotherapy of Cardiovascular Disease

View full text Add to dashboard Cite

Drugs with diversifi ed structure and class target the RAAS cascade at various levels. Beginning with the inhibition of renin from the juxtaglomerular cells of the kidney, it extends to the blockade of formation and actions of its principal component, Ang II, and its effector, aldosterone and its synthesis. Although all of them are very effi cacious in combating overactivation of RAAS, ACE inhibitors and ARBs stand out in the armamentarium of RAAS inhibitors. All of them are effective in lowering blood pressure but differ from each other in potency, pharmacokinetic properties and additional pharmacologic actions that are contributed by their unique functional groups. Therapeutic uses of RAAS blockers stem from the dynamics of the complex intertwined downstream signaling molecules that interact to contribute beyond blood pressure control. Thus, some of the ACE inhibitors and ARBs are also indicated in the treatment of heart failure, left ventricular dysfunction following myocardial infarction, and nephropathy in T2DM, reducing the risk of cardiovascular mortality, nonfatal myocardial infarction, and the risk of developing heart failure. Several studies have investigated the dual inhibition of the RAAS in hypertension and heart failure with an outcome of more adverse events without an increase in benefi t. While considering Ang II and aldosterone escape processes during ACE inhibitors and ARBs therapies, RAAS at the base level can be halted using aldosterone receptor antagonists for the management of hypertension and heart failure. InThe opinions expressed herein are those of GJ and do not necessarily refl ect those of the US Food and Drug Administration.

show abstract

“…15 Earlier studies have shown the effectiveness of trandolapril as part of a titration based, escalating dose antihypertensive regimen, both in treatment-naïve subjects and those uncontrolled on diuretics or CCB. 16 …”

Section: Introductionmentioning

confidence: 97%